REFERENCES
- Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt study. AIDS. 2000;14:1333–1339.
- Inaba T, Fischer NE, Riddick DS, et al. HIV protease inhibi-tors, saquinavir, indinavir and ritonavir: Inhibition of CYP3A4 mediated metabolism of testosterone and binzoxazinorifamycin, KRM-1648, in human liver mi-crosomes. Toxicol Lett. 1997;93:215–219.
- Gutmann H, Fricker G, Drewe J, et al. Interactions of HIV protease inhibitors with ATP-dependent drug export pro-teins. Mol PharmacoL 1999;56:383–389.
- Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst agents used to treat patients with HIV infection. Clin Pharmacokinet. 1999;4:289–304.
- Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharm-cokinetics alone and in combination with ritonavir in HIV infected patients. AIDS. 1997;11:F29–F33.
- Kaufmann G, Duncombe C, Cunningham P, et al. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1 infected individuals. AIDS. 1998;12:1625–1630.
- Schinazi R, Larder B, Mellors J. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int Antiviral News. 2001;8(5):65–91.
- Condra J, Petropoulos C, Ziermann R, et al. Drug resis-tance and predicted virologic responses to human immundeficiency virus type 1 protease inhibitor therapy. J Infect Dis. 2000;182:758–765.
- Katlama C, Valantin MA, Matheron S, et al. Efficacy and tolerability of stavudine plus lamivudine in treatment-naïve and treatment-experienced patients with HIV infec-tion. Ann Intern Med. 1998;129:525–531.
- Smith D, Hales G, Roth N, et al. A randomised trial of nelfinavir, ritonavir or delaviridine in combination with saquinavir-SCG and stavudine, in treatment-experienced HIV-1 infected patients. HIV Clin Trials. 2001;2(2):97–107.
- Hertogs K, Bloor S, Larder B, et al. A novel human immu-nodeficiency virus type 1 reverse transcriptase pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother. 2000;44:568–573.
- Larder B, et al. Quantitative predicting of HIV-1 pheno-typic drug resistance from genotypes: The virtual pheno-type. Fourth International Workshop on HIV Drug Resis-tance & Treatment Strategies; June 2000; Sitges, Spain. Abstract 63.
- Sevin A, DeGruttola V, Nijhuis M, et al. Methods for inves-tigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS Clinical Trials Group 333. J Infect Dis. 2000;182:59–67.
- Hertogs K, Bloor S, Kemp S, et al. Phenotypic and geno-typic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: A survey of over 6000 samples. AIDS. 2000;14:1203–1210.
- Larder B, Wang D, Harrigan R. Use of genotypic and phenotypic data for optimal monitoring of HIV-1 drug resistance. In: Program and abstracts of HIV DART 2000-Frontiers in Drug Development for Antiretroviral Thera-pies; December 17–21, 2000; Isla Verde, Puerto Rico. Abstract 020.
- Pellegrin I, Segondy M, Garrigue I, et al. Phenotypic resis-tance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy. J Acquir Immune Defic Syndr. 2000;25(5):465–466.
- Kirk O, Terese L, Katzenstein D, et al. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: A randomized trial. AIDS. 1999;13:F9–F16.
- Tebas P, Patrick A, Kane E, et al. Virologic responses to a ritonavir-saquinavir containing regimen in patients who had previously failed nelfinavir. AIDS. 1999;13:F23–F28.
- Harrigan R, Hertogs K, Versbiest W, et al. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community set-ting. AIDS. 1999;13:1863–1871.